UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-KSB/A

[X]  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE ACT OF
     1934

                   For the fiscal year ended December 31, 1997

                                       OR

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934

      For the transition period from                  to                   

      Commission File No. 1-11109

                           LUKENS MEDICAL CORPORATION
                 ----------------------------------------------
                 (Name of small business issuer in its charter)

          Delaware                                        22-2429965
(State or other jurisdiction                (IRS Employer Identification Number)
      of incorporation)     

3820 Academy Parkway North NE
Albuquerque, New Mexico                                                87109
----------------------------------------                              ----------
(Address of principal executive offices)                              (Zip Code)

Issuer's telephone number, including are code                     (505) 342-9638
                                              ----------------------------------

Securities registered under Section 12(b) of the Exchange Act:

   Title of each class                 Name of each exchange on which registered
----------------------------           -----------------------------------------
Common Stock, $.01 par value                     Pacific Stock Exchange


Securities registered under Section 12 (g) of the Exchange Act:

                          Common Stock, $.01 par value
                          ----------------------------
                                (Title of Class)

     Check  whether  the issuer (1) filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days. Yes X No

     Check if the  disclosure  of  delinquent  filers in response to Item 405 of
Regulation  S-B is not  contained  in  this  form,  and no  disclosure  will  be
contained,  to the  best of  registrant's  knowledge,  in  definitive  proxy  or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]




<PAGE>



     State issuer's revenues for its most recent fiscal year: $8,618,863.

     State the aggregate market value of the voting stock held by non-affiliates
computed by reference  to the price at which the stock was sold,  or the average
bid and  asked  price  of such  stock,  as of March  25,  1998:  $7,002,820.  In
determining  the market value of voting stock held by  non-affiliates,  share of
Common Stock of the  registrant  beneficially  owned by directors,  officers and
holders  or more  than 10% of the  outstanding  shares  of  Common  Stock of the
registrant  have been excluded.  The  determination  of affiliate  status is not
necessarily a conclusive determination for other persons.

     State the number of shares  outstanding of each of the issuer's  classes of
common equity,  as of March 1, 1998:  3,043,359 shares of Common Stock, $.01 par
value.




                                       2

<PAGE>




     The undersigned  Registrant hereby amends the following items of its Annual
Report on Form 10-KSB for the fiscal year ended  December 31, 1997, as set forth
in the pages attached hereto:


     Item 9 - Directors,  Executive  Officers,  Promoters  and Control  Persons;
Compliance with Section 16(a) of the Exchange Act.
     Item 10 - Executive Compensation.
     Item 11 - Security Ownership of Certain Beneficial Owners and Management.
     Item 12 - Certain Relationships and Related Transactions.










                                       3

<PAGE>




                                    PART III

ITEM 9.   DIRECTORS,   EXECUTIVE   OFFICERS,   PROMOTERS  AND  CONTROL  PERSONS;
          COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

          The directors and executive officers of the Company are as follows:

<TABLE>
<CAPTION>
         Name                      Age       Position(s) with the Company
         -------------------       ---       -----------------------------------------------------
<S>                                <C>       <C>
         John H. Robinson          75        Director

         Robert S. Huffstodt       39        President, Chief Executive Officer
                                             and Director

         Robert L. Priddy          51        Chairman of the Board of Directors

         John P. Holmes            60        Director

         Michael E. Sobieski       44        Chief Financial Officer and Vice President of Finance

         Gary K. Porter            39        Vice President, Sales and Marketing
</TABLE>

     JOHN H.  ROBINSON,  a director of the Company  since April 17,  1995,  is a
private investor.  From 1993 through 1997, Mr. Robinson was an executive officer
and director of  Commonwealth  Associates  Management  Company,  Inc.,  the sole
general partner of Commonwealth  Associates,  an investment  banking firm in New
York.  Prior to that  time,  Mr.  Robinson  was  President,  Chairman  and Chief
Executive  Officer  of The  Harper  Group,  a freight  forwarding  company.  Mr.
Robinson is also currently a director of LBU, Inc.

     ROBERT S. HUFFSTODT,  has been President and Chief Executive Officer of the
Company  since  November 4, 1994 and a director of the  Company  since  November
1992. He also served as Chairman of the Board from March 1, 1995 through July 6,
1995. Mr. Huffstodt joined the Company as Controller in October 1983.

     ROBERT L. PRIDDY,  a director of the Company since March 1, 1995,  has been
Chairman of the Board since  December  1997.  Mr. Priddy is a private  investor.
Since  June  1993,  Mr.  Priddy  has been on the Board of  Directors  of Airtran
Holdings,  formerly known as ValuJet,  Inc. Since June 1997, Mr. Priddy has been
on the Board of Directors of AccuMed International.

     JOHN P.  HOLMES,  a director  of the Company  since  January  1998,  and is
currently President of John P. Holmes & Company,  Inc., a merchant banking firm.
He is a former  chairman of the  Management  Committee of Oppenheimer & Company.
Mr. Holmes is also currently a director of Penn Octane Corporation.

     MICHAEL E. SOBIESKI, joined the Company as Chief Financial Officer and Vice
President  of Finance in December  1997.  Prior to that time,  Mr.  Sobieski was
corporate  controller of Cotrell Ltd., a medical device  company,  from February
1997  through  November  1997.  During  1996,  Mr.  Sobieski  was  engaged in an
entrepreneurial  venture.  From 1974 through  February 1996,  Mr.  Sobieski held
various financial support positions at Storage Technology Corporation.



                                       4

<PAGE>



     GARY K. PORTER,  JR. joined the Company in 1994 and has been Vice President
of Sales and Marketing since 1995. Prior to joining the Company,  Mr. Porter was
a manager in the Sales and Marketing Department of Deknatel, Inc.

     COMPLIANCE  WITH SECTION 16(A) OF THE EXCHANGE ACT.  Based on the Company's
review of reports filed by Directors, Executive Officers and 10% shareholders of
the  Company on Forms 3, 4 and 5 pursuant  to Section 16 of the  Securities  and
Exchange  Act of 1934,  all such  reports  were filed on a timely  basis  during
fiscal year 1997 except that (I) Mr.  Robinson failed to timely file two reports
on Form 4 to report the acquisition of certain  warrants from the Company,  (ii)
Mr. Priddy failed to timely file two reports on Form 4 to report the  aquisition
of certain warrants from the Company and one report on Form 4 to report the sale
of certain  shares of the  Company's  Common  Stock,  (iii) Mr. Holmes failed to
timely  file a  report  on Form 3 to  report  his  appointent  to the  Board  of
Directors of the Company,  (iv) Mr.  Huffstodt failed to timely file a report on
Form 4 to report the  exercise  of certain  employee  stock  options and (v) Mr.
Sobieski  failed to timely file a report on Form 3 to report his  appointment as
Chief Financial  Officer of the Company.  All such delinquent  reports have been
filed.

ITEM 10.  EXECUTIVE COMPENSATION

     The  following  summary  compensation  table  sets forth  information  with
respect  to the  aggregate  compensation  paid and  accrued by the  Company  for
services  rendered  in all  capacities  to the  Company  during the years  ended
December 31, 1995, 1996, and 1997 for the Company's Chief Executive Officer (the
"Named Executive  Officer").  No other Executive Officer of the Company received
annual  compensation  from the Company in excess of $100,000  for the year ended
December 31, 1997.

<TABLE>
<CAPTION>
                           SUMMARY COMPENSATION TABLE

                                                                        Long Term
                                  Annual Compensation                 Compensation
                                  -------------------                 ------------
                                                                Securities
                                                                Underlying      All Other
Name and Principal Position     Year   Salary    Bonus   Other    Options    Compensation(1)
---------------------------     ----   ------    -----   -----    -------    --------------
<S>                             <C>    <C>         <C>    <C>    <C>         <C>     
Robert S. Huffstodt, ........   1997   $163,350   -0-     -0-     100,000     $  4,750
President and Chief Executive   1996   $148,500   -0-     -0-      30,000     $  4,455
Officer .....................   1995   $135,000   -0-     -0-      45,000     $  4,050
</TABLE>


----------
(1)  Represents Company contributions to 401(k) Plan.

     EMPLOYMENT  AGREEMENT.  On January 10, 1995, the Company entered into a new
employment agreement with Robert S. Huffstodt, the Company's President and Chief
Executive  Officer.  The  Employment  Agreement  has a term of three  years  and
automatically  renews for successive  one-year terms thereafter unless notice to
not renew is  provided  not less than six months  prior to the end of such term.
Mr. Huffstodt is currently paid a salary of $163,350 per annum with increases to
be  provided  subject  to annual  review  by the Board and based  upon a cost of
living  adjustment and the net income of the Company.  Mr. Huffstodt was granted
options  to  purchase  15,000  shares  of  Common  Stock  (which  vest in  equal
installments  over  a  four-year  period)  in  connection  with  the  Employment
Agreement  and is  entitled  to receive a bonus of up to 35% of his base  salary
based upon the Company achieving certain performance targets established jointly
by Mr.  Huffstodt  and the  Board.  Mr.  Huffstodt  has also  agreed to  certain
confidentiality  provisions  and  not to  directly  or  indirectly  engage  in a
competing business or solicit the Company's customers or employees for two years
from the termination of his employment with the Company.




                                       5

<PAGE>



     1992 STOCK OPTION PLAN. In March 1992,  the Company  adopted the 1992 Stock
Option Plan (the "Plan") which currently  covers 850,000 shares of the Company's
Common  Stock,  pursuant to which  officers,  directors and key employees of the
Company are eligible to receive  incentive and/or  non-qualified  stock options.
The Plan,  which expires on March 10, 2002, is administered by the  Compensation
Committee.  Options granted under the Plan are exercisable for a period of up to
10 years from the date of grant at an exercise  price which is not less than the
fair market value of the Common Stock on the date of the grant,  except that the
term of an incentive stock option granted under the Plan to a stockholder owning
more than 10% of the outstanding  Common Stock may not exceed five years and its
exercise  price may not be less than 110% of the fair market value of the Common
Stock on the date of the grant.  A total of 751,325  shares of Common  Stock are
presently subject to outstanding options under the plan.

     The following table sets forth  information with respect to grants of stock
options during the year ended December 31, 1997 to the Named Executive Officer:

<TABLE>
<CAPTION>
                      OPTION GRANTS IN THE LAST FISCAL YEAR

                           Number of                 Percent of Total
                           Securities                Options Granted to
                           Underlying Options        Employees in              Exercise or
Name                       Granted                   Fiscal Year               Base Price        Expiration Date
----                       ------------------        ------------------        -----------       ---------------
<S>                                 <C>                  <C>                   <C>               <C>
Robert S. Huffstodt                 50,000(1)            30.4 %                $5.00             01/01/02
                                    50,000(2)            30.4 %                $6.25(3)          02/21/01
</TABLE>

----------
(1)  Vest in  equal  monthly  installments  over a  four-year  period  beginning
     January 2, 1997.
(2)  Vest in equal monthly  installments over a four-year period beginning March
     21, 1997.
(3)  Originally  issued at an exercise price of $8.25 per share and subsequently
     repriced to $6.25 per share.


     The following table sets forth information with respect to each exercise of
stock  options  during  the  year  ended  December  31,  1997  and the  value of
unexercised options at that date for the Named Executive Officer.

<TABLE>
<CAPTION>
 AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUE TABLE

                                                                       Number of
                                                                       Securities
                                                                       Underlying
                                                                       Unexercised           Value of Unexercised
                                                                       Options/SARs at       In-the-Money
                                                                       FY-End                Options/SARs at FY-
                           Shares Acquired                             Exercisable/          End Exercisable/
Name                       on Exercise           Value Received        Unexercisable         Unexercisable
----                       ---------------       --------------        ---------------       --------------------
<S>                           <C>                   <C>                <C>                     <C>
Robert S. Huffstodt           22,846                $67,885            60,313/114,687          $2,735/$0
</TABLE>






                                       6

<PAGE>




ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

                  Set forth below is information  concerning  stock ownership of
all  persons  known  by  the  Company  to own  beneficially  5% or  more  of the
outstanding shares of Common Stock of the Company, based on information provided
to the Company,  each Director of the Company,  the Named Executive  Officer and
all  Executive  Officers and Directors of the Company as a group as of March 31,
1998:

<TABLE>
<CAPTION>
         Name and Address of                                  Nature and Amount of
         Beneficial Owner                                     Beneficial Ownership (1)       Percentage of Class
         ----------------                                     ------------------------       -------------------
<S>                                                           <C>                                <C>  
         John H. Robinson                                     927,000(2)                         26.1%
         RJH Enterprises
         260 Townsend Street, 2nd Floor
         San Francisco, CA  94107

         Robert L. Priddy                                     493,300(3)                         15.2%
         3435 Kingsboro Road #1601
         Atlanta, GA  30326

         Robert S. Huffstodt                                   85,349(4)                          2.7%
         Lukens Medical Corporation
         3820 Academy Parkway North NE
         Albuquerque, NM 87109

         John P. Holmes                                       119,500(5)                          3.8%
         John P. Homes & Company, Inc.
         P.O. Box 428
         Shelter Island Heights, NY 11965

         All officers and directors as a group                1,646,749(6)                       42.7%
         (6 persons)
</TABLE>

----------

(1)  Unless otherwise  indicated below, the persons in the above table have sole
     voting  and  investment  power  with  respect  to shares  of  Common  Stock
     beneficially owned by them.

(2)  Includes  immediately  exercisable  warrants to purchase  450,000 shares of
     Common Stock.  Includes  currently  exercisable  options to purchase  6,000
     shares of Common Stock.

(3)  Includes  immediately  exercisable  warrants to purchase  50,000  shares of
     Common Stock and currently  exercisable  options to purchase 106,000 shares
     of Common Stock.

(4)  Includes  options  exercisable  within 60 days to purchase 77,292 shares of
     Common Stock.

(5)  Includes  immediately  exercisable  options to  purchase  50,000  shares of
     Common  Stock.  The  shares of Common  Stock are owned by John P.  Holmes &
     Company, Inc., a company controlled by Mr. Holmes.

(6)  See footnotes 2 through 5 hereof.


                                       7

<PAGE>




ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

     On April 13,  1995,  the Company  entered  into an  agreement  with John H.
Robinson, a director of the Company, whereby Mr. Robinson (i) loaned $400,000 to
the  Company  (the "April  Loan"),  (ii) agreed to  purchase,  at the  Company's
request at any time prior to March 31,  1996,  up to $500,000  of the  Company's
Common Stock at the market price at the time of such  investment,  and (iii) was
issued 400,000 five-year  warrants to purchase Common Stock at an exercise price
of $1.10 per share.  The April Loan bears  interest at the rate of 8% per annum,
and all principal and interest  accrued  during the term thereof is deferred and
payable on April 15,  1999.  Proceeds  of the April Loan were used to reduce the
Company's  outstanding  indebtedness  under its line of credit  with its lending
bank by $350,000 and the remainder was used for general corporate  purposes.  On
September 11, 1995, Mr.  Robinson  loaned the Company an additional  $250,000 to
partially  finance  the  payoff of  certain  capitalized  leases in  respect  of
equipment (the "Buyout Loan").  The Buyout Loan bears interest at the rate of 8%
per annum and all  principal  and  interest  accrued  during the term thereof is
deferred and payable in October, 1999. On March 5, 1996, Mr. Robinson loaned the
Company  $400,000  to fund a  portion  of the  purchase  price  relating  to the
Company's  acquisition of three product lines from Ulster Scientific,  Inc. (the
"Acquisition  Loan"). The Acquisition Loan bears interest at the rate of 10% per
annum and all principal and interest accrued during the term thereof is deferred
and payable on September 5, 2000.  Repayment of the April Loan,  the Buyout Loan
and the Acquisition  Loan are  subordinated to the Company's line of credit with
its lending  bank. At the request of the  Company's  lending bank,  the previous
maturity dates thereunder were extended for two additional years to the maturity
dates reflected above.

     As of March 1, 1996, the Company  entered into a consulting  agreement with
John H. Robinson,  a director of the Company.  Such  consulting  agreement has a
term of one year and thereafter  automatically  renews for  additional  one-year
periods unless previously  canceled by either party. Mr. Robinson is entitled to
receive  approximately $50,000 per year pursuant to the terms of such consulting
agreement.  Such consulting  agreement is terminable by either party at any time
after  the  first  year  upon 60 days'  prior  written  notice.  Mr.  Robinson's
consulting agreement is still in effect.

     On February 28, 1997,  the Company  entered into an agreement  with John H.
Robinson and Robert L. Priddy,  each a director and  substantial  stockholder of
the Company, whereby Messrs. Robinson and Priddy loaned the Company an aggregate
of  $1,000,000.  Such loans  bear  interest  at the rate of 10% per  annum,  are
repayable  on or  before  January  1, 1999 and are  subordinated  to the Line of
Credit. In connection  therewith,  Messrs.  Robinson and Priddy were each issued
warrants to purchase 15,000 shares of Common Stock at an exercise price of $6.25
per share, and warrants to purchase an additional  35,000 shares of Common Stock
at $6.25 per share.





                                       8

<PAGE>



                                   SIGNATURES

     In accordance  with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                              LUKENS MEDICAL CORPORATION

                                              By: /s/ Robert S. Huffstodt
                                                  ------------------------------
                                                  Robert S. Huffstodt, President

                                              Date: April 29, 1998


     In  accordance  with the Exchange Act, this report has been signed below by
the following  persons on behalf of the  registrant and in the capacities and on
the dates indicated.

<TABLE>
<CAPTION>
         SIGNATURE AND TITLE                                                   DATE
<S>                                                                        <C>
         /s/ Robert S. Huffstodt                                           April 29, 1998
-------------------------------------------------------------------
Robert S. Huffstodt
President and Chief Executive Officer (Principal Executive Officer)

         /s/ Michael Sobieski                                              April 29, 1998
-------------------------------------------------------------------
Michael Sobieski
Chief Financial Officer (Principal Financial Officer
and Principal Accounting Officer)

         /s/ John H. Robinson                                              April 29, 1998
-------------------------------------------------------------------
John H. Robinson
Director

         /s/ Robert L. Priddy                                              April 29, 1998
-------------------------------------------------------------------
Robert L. Priddy
Chairman of the Board of Directors

         /s/ John P. Holmes                                                April 29, 1998
-------------------------------------------------------------------
John P. Holmes
Director
</TABLE>



                                       9